Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

dc.creatorFinn, RS
dc.creatorRyoo, BY
dc.creatorMerle, P
dc.creatorBouattour, M
dc.creatorLim, HY
dc.creatorBreder, V
dc.creatorEdeline, J
dc.creatorChao, Y
dc.creatorOgasawara, S
dc.creatorYau, T
dc.creatorGarrido, M
dc.creatorChan, SL
dc.creatorKnox, J
dc.creatorDaniele, B
dc.creatorEbbinghaus, SW
dc.creatorChen, E
dc.creatorSiegel, AB
dc.creatorZhu, AX
dc.creatorCheng, AL
dc.date.accessioned2020-05-19T20:43:01Z
dc.date.available2020-05-19T20:43:01Z
dc.date.created2020-05-19T20:43:01Z
dc.date.issued2020
dc.identifier10.1200/JCO.19.01307
dc.identifier0732-183X
dc.identifierhttps://doi.org/10.1200/JCO.19.01307
dc.identifierhttps://repositorio.uc.cl/handle/11534/29032
dc.languageen
dc.titlePembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
dc.typeartículo


Este ítem pertenece a la siguiente institución